IDEXX Labs surges over 3% as second quarter earnings beat expectations

Published 04/08/2025, 11:40
 IDEXX Labs surges over 3% as second quarter earnings beat expectations

WESTBROOK, Maine - On Monday, IDEXX Laboratories (NASDAQ:IDXX) reported second quarter earnings that exceeded analyst expectations, driven by strong instrument placements and solid recurring diagnostic revenue growth.

The pet healthcare innovation company’s shares rose +3.63% in pre-market trading after the earnings release.

The company posted adjusted earnings of $3.63 per share, beating analyst estimates of $3.29, while revenue climbed 11% to $1.11 billion, surpassing the consensus forecast of $1.06 billion. Organic revenue growth was 9% for the quarter, supported by Companion Animal Group (CAG) Diagnostics recurring revenue growth of 7% on an organic basis.

IDEXX achieved record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx placements, highlighting strong adoption of its slide-free technology. The company’s IDEXX VetLab consumables generated 15% reported revenue growth and 14% organic growth, reflecting increased testing utilization across regions.

The company raised its full-year 2025 guidance, now expecting revenue of $4.205-$4.28 billion, up from its previous forecast of $4.095-$4.21 billion and above analyst consensus of $4.149 billion. IDEXX also increased its EPS outlook to $12.40-$12.76, compared to the prior guidance of $11.93-$12.43 and analyst expectations of $12.21.

Operating margin for the quarter was 33.6%, improving by 130 basis points on a comparable basis, supported by strong growth in high-margin consumables revenue and reference lab productivity initiatives.

International markets showed particularly strong performance, with CAG Diagnostics recurring revenue growing 15% as reported and 11% organically in international regions, compared to 6% growth in the U.S.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.